emicizumab biosimilar / Sandoz, mAbxience - LARVOL DELTA

Sandoz announces collaboration with mAbxience to expand patient access to life-enhancing biosimilar medicines (Sandoz Press Release) - "The agreement paves the way for the two companies to collaborate on a proposed emicizumab biosimilar, currently in early-stage development....Under the terms of the agreement, Sandoz will have exclusive global commercialisation rights for the proposed emicizumab biosimilar, excluding Argentina, Uruguay and Paraguay, while mAbxience will be responsible for development and manufacturing. Both parties have agreed to keep the financial terms of the agreement confidential. The agreement also provides a basis for the two companies to evaluate potential future collaboration opportunities based on their shared commitment to expanding patient access to biosimilar medicines around the world."

Licensing / partnership • Hemophilia A